DURHAM, N.C. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at
- Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today reported financial results and provided a corporate update for the third
DURHAM, N.C. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H., Chief Executive Officer and Tim Trost, Chief Financial
DURHAM, N.C. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Thursday, November 8, 2018 at 8:30 a.m.
Data supports further clinical evaluation of brincidofovir for the treatment and prevention of BK virus DURHAM, N.C. , Oct. 27, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced data from two preclinical studies which assessed the in vivo antiviral activity of brincidofovir (BCV)
DURHAM, N.C. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host the Company's annual investor update on October 17, 2018, at 4:30 p.m. ET in New York .
DURHAM, N.C. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from the company’s Phase 1 study evaluating the safety and pharmacokinetics (PK) of multiple ascending doses (MAD) of
– First Study to Show that Adenovirus Area Under the Curve is an Optimal Indicator of Clinical Outcomes in Adenovirus Infection – DURHAM, N.C. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today
DURHAM, N.C. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present a corporate
DURHAM, N.C. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that company management will participate in upcoming investor conferences in September.
